ConductScience.org, home
Study of Lemborexant for Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia
API referenceFor AI assistants

Trial · NCT03001557

Results by group574

Each measurement the trial posted, group by group, in the words and numbers it posted.

1 to 20 of 574

Download this page as JSON
OutcomeGroupCategoryValueSpreadUnits
Core Phase: Change From Baseline in Mean Actigraphy Sleep Efficiency (aSE) With Lemborexant Compared to Placebo During Week 1 of TreatmentCore Phase: Lemborexant-matched PlaceboBaseline76.34Standard Deviation 6.559percentage of sleep time
Core Phase: Change From Baseline in Mean Actigraphy Sleep Efficiency (aSE) With Lemborexant Compared to Placebo During Week 1 of TreatmentCore Phase: Lemborexant 2.5 mgBaseline77.64Standard Deviation 7.883percentage of sleep time
Core Phase: Change From Baseline in Mean Actigraphy Sleep Efficiency (aSE) With Lemborexant Compared to Placebo During Week 1 of TreatmentCore Phase: Lemborexant 5 mgBaseline78.45Standard Deviation 6.844percentage of sleep time
Core Phase: Change From Baseline in Mean Actigraphy Sleep Efficiency (aSE) With Lemborexant Compared to Placebo During Week 1 of TreatmentCore Phase: Lemborexant 10 mgBaseline76.38Standard Deviation 8.037percentage of sleep time
Core Phase: Change From Baseline in Mean Actigraphy Sleep Efficiency (aSE) With Lemborexant Compared to Placebo During Week 1 of TreatmentCore Phase: Lemborexant 15 mgBaseline77.35Standard Deviation 8.624percentage of sleep time
Core Phase: Change From Baseline in Mean Actigraphy Sleep Efficiency (aSE) With Lemborexant Compared to Placebo During Week 1 of TreatmentCore Phase: Lemborexant-matched PlaceboChange at Week 10.14Standard Deviation 5.766percentage of sleep time
Core Phase: Change From Baseline in Mean Actigraphy Sleep Efficiency (aSE) With Lemborexant Compared to Placebo During Week 1 of TreatmentCore Phase: Lemborexant 2.5 mgChange at Week 12.43Standard Deviation 3.910percentage of sleep time
Core Phase: Change From Baseline in Mean Actigraphy Sleep Efficiency (aSE) With Lemborexant Compared to Placebo During Week 1 of TreatmentCore Phase: Lemborexant 5 mgChange at Week 13.87Standard Deviation 4.646percentage of sleep time
Core Phase: Change From Baseline in Mean Actigraphy Sleep Efficiency (aSE) With Lemborexant Compared to Placebo During Week 1 of TreatmentCore Phase: Lemborexant 10 mgChange at Week 1-0.17Standard Deviation 5.861percentage of sleep time
Core Phase: Change From Baseline in Mean Actigraphy Sleep Efficiency (aSE) With Lemborexant Compared to Placebo During Week 1 of TreatmentCore Phase: Lemborexant 15 mgChange at Week 10.05Standard Deviation 4.475percentage of sleep time
Core Phase: Change From Baseline in Mean aSE With Lemborexant Compared to Placebo During Week 2 of TreatmentCore Phase: Lemborexant-matched PlaceboBaseline76.34Standard Deviation 6.559percentage of sleep time
Core Phase: Change From Baseline in Mean aSE With Lemborexant Compared to Placebo During Week 2 of TreatmentCore Phase: Lemborexant 2.5 mgBaseline77.64Standard Deviation 7.883percentage of sleep time
Core Phase: Change From Baseline in Mean aSE With Lemborexant Compared to Placebo During Week 2 of TreatmentCore Phase: Lemborexant 5 mgBaseline78.45Standard Deviation 6.844percentage of sleep time
Core Phase: Change From Baseline in Mean aSE With Lemborexant Compared to Placebo During Week 2 of TreatmentCore Phase: Lemborexant 10 mgBaseline76.38Standard Deviation 8.037percentage of sleep time
Core Phase: Change From Baseline in Mean aSE With Lemborexant Compared to Placebo During Week 2 of TreatmentCore Phase: Lemborexant 15 mgBaseline77.35Standard Deviation 8.624percentage of sleep time
Core Phase: Change From Baseline in Mean aSE With Lemborexant Compared to Placebo During Week 2 of TreatmentCore Phase: Lemborexant-matched PlaceboChange at Week 2-1.31Standard Deviation 7.004percentage of sleep time
Core Phase: Change From Baseline in Mean aSE With Lemborexant Compared to Placebo During Week 2 of TreatmentCore Phase: Lemborexant 2.5 mgChange at Week 22.17Standard Deviation 2.833percentage of sleep time
Core Phase: Change From Baseline in Mean aSE With Lemborexant Compared to Placebo During Week 2 of TreatmentCore Phase: Lemborexant 5 mgChange at Week 21.65Standard Deviation 4.644percentage of sleep time
Core Phase: Change From Baseline in Mean aSE With Lemborexant Compared to Placebo During Week 2 of TreatmentCore Phase: Lemborexant 10 mgChange at Week 2-1.41Standard Deviation 5.896percentage of sleep time
Core Phase: Change From Baseline in Mean aSE With Lemborexant Compared to Placebo During Week 2 of TreatmentCore Phase: Lemborexant 15 mgChange at Week 2-0.07Standard Deviation 5.449percentage of sleep time

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Next page

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03001557/results

API referenceFor AI assistants